Effects of Recombinant Insulin-like Growth Factor I on Insulin Secretion and Renal Function in Normal Human Subjects

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1989 Apr 1

PMID 2649897

Citations 58

Authors

H P Guler

C Schmid

J Zapf

E R FROESCH

Affiliations

Soon will be listed here.

Abstract

Insulin-like growth factor I (IGF-I) is an important mediator of growth hormone (GH) action and it appeared tempting to evaluate possible clinical applications. Recombinant IGF-I was infused s.c. at a dose of 20 micrograms/kg of body weight per hour during 6 days in two healthy adult subjects. Blood glucose and fasting insulin levels remained within normal limits and IGF-II levels were suppressed. In contrast to insulin, fasting C peptide levels were decreased. GH secretion was also suppressed by IGF-I. Our preliminary data allow us to distinguish between the effects of GH per se and those of IGF-I: GH causes hyperinsulinism, whereas IGF-I leads to decreased insulin secretion. Glomerular filtration rate, as estimated by creatinine clearance, increased to 130% of preinfusion values during the IGF-I infusion. Total creatinine and urea excretion remained unchanged. We conclude that IGF-I influences kidney function and, in contrast to GH, exerts an insulin-sparing effect. It may be speculated that the therapeutic spectrum of IGF-I is quite different from that of GH.

Citing Articles

Uric acid levels correlate with disease activity in growth hormone-secreting pituitary adenoma patients.

Mo C, Chen H, Wang F, Guo Y, Wang Y, Tong T Front Endocrinol (Lausanne). 2023; 14:1230852.

PMID: 37818085 PMC: 10561298. DOI: 10.3389/fendo.2023.1230852.

SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes.

Schaub J, Alakwaa F, McCown P, Naik A, Nair V, Eddy S J Clin Invest. 2023; 133(5).

PMID: 36637914 PMC: 9974101. DOI: 10.1172/JCI164486.

Youth versus adult-onset type 2 diabetic kidney disease: Insights into currently known structural differences and the potential underlying mechanisms.

Tommerdahl K, Kendrick J, Nelson R, Bjornstad P Clin Sci (Lond). 2022; 136(21):1471-1483.

PMID: 36326718 PMC: 10175439. DOI: 10.1042/CS20210627.

Growth Hormone and IGF1 Actions in Kidney Development and Function.

Gurevich E, Segev Y, Landau D Cells. 2021; 10(12).

PMID: 34943879 PMC: 8699155. DOI: 10.3390/cells10123371.

Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer.

Kasprzak A Int J Mol Sci. 2021; 22(12).

PMID: 34208601 PMC: 8234711. DOI: 10.3390/ijms22126434.

References

Roth J, Kahn C, Lesniak M, Gorden P, De Meyts P, MEGYESI K . Receptors for insulin, NSILA-s, and growth hormone: applications to disease states in man. Recent Prog Horm Res. 1975; 31:95-139. DOI: 10.1016/b978-0-12-571131-9.50007-4. View

IKKOS D, Luft R, GEMZELL C . The effect of human growth hormone in man. Acta Endocrinol (Copenh). 1959; 32:341-61. DOI: 10.1530/acta.0.xxxii0341. View

DErcole A, Decedue C, Furlanetto R, Underwood L, Van Wyk J . Evidence that somatomedin-C is degraded by the kidney and inhibits insulin degradation. Endocrinology. 1977; 101(2):577-86. DOI: 10.1210/endo-101-2-577. View

Schwartz J . Enhanced sensitivity to insulin in rats treated with antibodies to rat growth hormone. Endocrinology. 1980; 107(4):877-83. DOI: 10.1210/endo-107-4-877. View

Berelowitz M, Szabo M, Frohman L, Firestone S, Chu L, Hintz R . Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science. 1981; 212(4500):1279-81. DOI: 10.1126/science.6262917. View

Zapf J, Walter H, FROESCH E . Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. J Clin Invest. 1981; 68(5):1321-30. PMC: 370928. DOI: 10.1172/jci110379. View

Schoenle E, Zapf J, HUMBEL R, FROESCH E . Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature. 1982; 296(5854):252-3. DOI: 10.1038/296252a0. View

Abe H, Molitch M, Van Wyk J, Underwood L . Human growth hormone and somatomedin C suppress the spontaneous release of growth hormone in unanesthetized rats. Endocrinology. 1983; 113(4):1319-24. DOI: 10.1210/endo-113-4-1319. View

Viberti G, Keen H . The patterns of proteinuria in diabetes mellitus. Relevance to pathogenesis and prevention of diabetic nephropathy. Diabetes. 1984; 33(7):686-92. DOI: 10.2337/diab.33.7.686. View

10.

Yamashita S, Melmed S . Insulin-like growth factor I action on rat anterior pituitary cells: suppression of growth hormone secretion and messenger ribonucleic acid levels. Endocrinology. 1986; 118(1):176-82. DOI: 10.1210/endo-118-1-176. View

11.

Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R . Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol. 1986; 250(3 Pt 1):E269-73. DOI: 10.1152/ajpendo.1986.250.3.E269. View

12.

Roelfsema F, Frolich M, Nieuwenhuijzen Kruseman A, Looij B . Glucagon-stimulated plasma C-peptide and insulin levels in active and non-active acromegalics. Clin Endocrinol (Oxf). 1985; 23(6):627-34. DOI: 10.1111/j.1365-2265.1985.tb01123.x. View

13.

Zapf J, Hauri C, WALDVOGEL M, FROESCH E . Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. J Clin Invest. 1986; 77(6):1768-75. PMC: 370532. DOI: 10.1172/JCI112500. View

14.

Scheiwiller E, Guler H, Merryweather J, Scandella C, Maerki W, Zapf J . Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I. Nature. 1986; 323(6084):169-71. DOI: 10.1038/323169a0. View

15.

Ueda I, VAN DEN BRANDE J . Biosynthetic somatomedin C (SM-C/IGF-I) increases the length and weight of Snell dwarf mice. Pediatr Res. 1986; 20(9):825-7. DOI: 10.1203/00006450-198609000-00002. View

16.

Guler H, Zapf J, FROESCH E . Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med. 1987; 317(3):137-40. DOI: 10.1056/NEJM198707163170303. View

17.

Guler H, Zapf J, Scheiwiller E, FROESCH E . Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci U S A. 1988; 85(13):4889-93. PMC: 280542. DOI: 10.1073/pnas.85.13.4889. View

18.

CORVILAIN J, ABRAMOW M, BERGANS A . Some effects of human growth hormone on renal hemodynamics and on tubular phosphate transport in man. J Clin Invest. 1962; 41:1230-5. PMC: 291036. DOI: 10.1172/JCI104584. View

19.

Kahn C, MEGYESI K, Roth J . Nonsuppressible insulin-like activity of human serum. A potent inhibitor of insulin degradation. J Clin Invest. 1976; 57(2):526-9. PMC: 436679. DOI: 10.1172/JCI108306. View